Basit öğe kaydını göster

dc.contributor.authorOk, Engin
dc.contributor.authorSaip, Pinar
dc.contributor.authorUras, Cihan
dc.contributor.authorDemircan, Orhan
dc.contributor.authorIsikdogan, Abdurrahman
dc.contributor.authorOzmen, Vahit
dc.contributor.authorAtasoy, Ajlan
dc.contributor.authorGökmen, Erhan
dc.contributor.authorOzdogan, Mustafa
dc.contributor.authorGuler, Nilufer
dc.date.accessioned2021-03-04T13:31:29Z
dc.date.available2021-03-04T13:31:29Z
dc.identifier.citationOzmen V., Atasoy A., Gökmen E., Ozdogan M., Guler N., Uras C., Ok E., Demircan O., Isikdogan A., Saip P., "Impact of Oncotype DX Recurrence Score on Treatment Decisions: Results of a Prospective Multicenter Study in Turkey", CUREUS, cilt.8, 2016
dc.identifier.othervv_1032021
dc.identifier.otherav_7cd5cc3a-6e2f-47ec-a24f-c5a854f6d16c
dc.identifier.urihttp://hdl.handle.net/20.500.12627/85356
dc.identifier.urihttps://doi.org/10.7759/cureus.522
dc.description.abstractIntroduction: Breast cancer is the most common malignancy among Turkish women and the rate of early stage disease is increasing. The Oncotype DX (R) 21-gene assay is predictive of distant recurrence in ER-positive, HER2-negative early breast cancer. We aimed to evaluate the impact of the Recurrence Score (R) (RS) on treatment decisions and physician perceptions in Turkey. We also studied correlations between RS and routine risk factors.
dc.language.isoeng
dc.subjectSağlık Bilimleri
dc.subjectTemel Tıp Bilimleri
dc.subjectTıp
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectTIP, GENEL & İÇECEK
dc.titleImpact of Oncotype DX Recurrence Score on Treatment Decisions: Results of a Prospective Multicenter Study in Turkey
dc.typeMakale
dc.relation.journalCUREUS
dc.contributor.departmentİstanbul Üniversitesi , İstanbul Tıp Fakültesi , Cerrahi
dc.identifier.volume8
dc.contributor.firstauthorID2503164


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster